OPINION: Dr Ken Romeo 775-870-6942
1956 was the year that growth hormone therapy was first introduced. In 1956, the growth hormone was of pig origin. Studies in 1956 and 1957 that lasted approximately 3 weeks in length produced no effects in the administration of growth hormone in humans.
But the race had begun. By 1958 three laboratories began extracting hGH from human pituitaries, purified it and used it for clinical investigations.
Dosing and supply of hGH became a problem.Approximately 1 mg of hGH was needed to treat one patient per day. Thus, greater than 360 human pituitaries were needed per patient per year. So it comes as no shock that the availability of hGH was limited and was awarded on the basis of clinical research protocols approved by the National Pituitary Agency established in 1961
The race to produce hGH continued and by 1977 a centralized laboratory was established to extract all human pituitaries in the US. But still a hurdle existed. The widespread use of hGH was not possible even if a pituitary from each autopsy performed in the US was collected. Mathematically, this would only permit therapy for about 4,000 patients.
The mass production of rhGH required the identification of the gene structure of the hormone, so scientists began to experiment with the methodology that began in 1976 to make insulin by recombinant technology.
Then….Serendipity!!! “Serendipity” in drug discovery means the finding of one thing while looking for something else. This took place in approximately 1985 in the rhGH (hGH) process.
The creation of a synthetic rhGH was accompanied by unlimited supplies of the drug for investigation and therapy.
So that’s the history of human growth hormone but here’s the point: rhGH and hGH are drugs of potential abuse when used off label.
The FDA Package Insert states the indications for use of recombinant human growth hormone as:
“OMNITROPE® is a recombinant human growth hormone indicated for:
- • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi Syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature
- • Adult: Treatment of adults with either adult onset or childhood onset GHD (Growth Hormone Deficiency)” (Source: Omnitrope FDA Package Insert)
hGH/rhGH treats serious medical conditions but has become a staple in anti aging protocols. I cannot agree with utilizing rhGH as an anti aging treatment at this time.
The inappropriate use of rhGH by athletes and anti aging physicians should be a primary concern to society and should be halted. The abuse of prescribing rhGH in an attempt to retard the aging process needs to be fully investigated before rhGH becomes an off label treatment in anti aging medicine. Patient safety should always be a primary concern and natural substances are available to help with anti aging protocols that have few, if any, side effects. What’s more….they work!!!
Aging is not a disease. Rather it is a normal progress of life. Many safer alternatives exist in the world of anti aging rather than the administration of human growth hormone which has not been fully studied.
Yours in Health!
Dr. Ken Romeo
Dr. Ken Romeo is a Principal and Chief Clinical Data Coordinator for the Healthy Aging Research Foundation (HARF) in Reno, NV.
Though each article and/or opinion contained on this Blog is derived from published Clinical and Research data contained in various national and international databases with links provided, if used,
NO ARTICLE OR CONCLUSION IS MEANT TO DIAGNOSE, TREAT, PREVENT OR CURE DISEASE.
CONSULT YOUR HEALTH PROFESSIONAL BEFORE MAKING ANY CHANGES TO YOUR HEALTH REGIMEN.
Contact: DrKenRomeo1@yahoo.com (Reno, NV) 775-870-6942